Form 4: Travere CFO Sells Shares for Tax Obligations

Travere Therapeutics CFO Christopher R. Cline reported the sale of 573 common shares in two transactions to cover tax withholding obligations and pursuant to a pre-arranged trading plan.

Summary

• Christopher R. Cline, Chief Financial Officer of Travere Therapeutics, Inc. (TVTX), reported two sales of common stock.
• On September 3, 2025, 454 shares were sold at $18.2 per share. This sale was mandated by the Issuer to cover tax withholding obligations upon the settlement of vested restricted stock units and was not a discretionary trade.
• On September 4, 2025, 119 shares were sold at $19.71 per share. This sale was made pursuant to a Rule 10b5-1(c) written plan adopted on May 28, 2025, and also included shares to cover tax obligations from RSU vesting.
• Following these transactions, Mr. Cline beneficially owns 92,083 shares of Travere Therapeutics common stock directly.

Sentiment

Score: 5

Explanation: The filing reports routine, non-discretionary insider stock sales primarily for tax purposes and under a pre-arranged plan, which typically has a neutral impact on market sentiment regarding the company's fundamentals.

Positives

• The sales were primarily for tax withholding obligations related to vested restricted stock units, which is a common and non-discretionary event for executives.
• One sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured approach to equity management rather than a reactive, discretionary sale.

Negatives

• The total beneficial ownership of common stock by the CFO decreased by 573 shares (454 + 119).

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sale of 454 shares on September 3, 2025, represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units, mandated by the Issuer's equity incentive plans.
• The sale of 119 shares on September 4, 2025, was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c), and includes shares sold to cover tax obligations upon the vesting of restricted stock units.

Industry Context

This insider transaction is a routine event for executives receiving equity compensation and does not provide specific insights into broader industry trends or competitive landscape for Travere Therapeutics.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, non-discretionary sales by an executive for tax purposes, not indicative of a change in company outlook or management confidence.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

The reported sales by the CFO are routine 'sell to cover' transactions for tax obligations and under a Rule 10b5-1 plan. These are not discretionary sales signaling a change in management's view of the company's prospects, and therefore do not warrant a change in investment recommendation based solely on this filing.

Keywords

Travere Therapeutics, TVTX, Christopher R. Cline, CFO, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Rule 10b5-1, Equity Compensation